Evidence-based guidelines and recommendations for the prevention, early detection, and treatment of diabetes are critical to optimal health and outcomes for people with diabetes. It is well known that monotherapy cannot achieve glycemic control for many people. When initiating a second-line therapy, clinicians must select among several treatment options and look beyond glycemic lowering. This interactive session will discuss the evidence and best practices of care for people with diabetes, including a review of current American Diabetes Association pharmacotherapy standards of care and the preferred treatment options to improve A1c, cardio-metabolic and renal health, and reduce the risks associated with diabetes.

Upon successful completion of this knowledge-based CPE course, pharmacy technicians should be able to:
1. Summarize recent changes to the American Diabetes Association Management of Hyperglycemia in Type 2 Diabetes.
2. Describe recommendations for appropriately selecting glycemic-lowering medications to reduce ASCVD, HF and/or CKD risk in patients with type 2 diabetes.
3. Discuss contraindications and adverse effects for medications used in the treatment of diabetes. 

John A. Galdo, PharmD, MBA, BCPS, BCGP
Ross Bridge Pharmacy
Ceimpact

John A. Galdo does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Initial Release Date: February 1, 2021
Planned Expiration Date: February 1, 2024